A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Thalassemia

Interventions

DRUG: Etavopivat A
DRUG: Etavopivat B
DRUG: Etavopivat C

Sponsor

Novo Nordisk A/S